Download - L5: Adrenergic agonists; sympathomimetics
April 10, 2023 1
Adrenergic agonists
Sympathomimetics drugs
Pharmacology I/ Lecture 5Dr. Hiwa K. Saaed, HD, M.Sc, Ph.D
April 10, 2023 2
agents that act on pathways mediated by the endogenous catecholamines (CAO); 1. norepinephrine2. epinephrine.
NEP & EP are modulate the Rate and force of contraction of heart. Resistance (constriction and dilation) of
blood vessels and bronchioles. Release of insulin, breakdown of fat (lipolysis).
Adrenergic agonists
April 10, 2023 3
synthesis, storage, release, binding removal (reuptake) of the neurotransmitter
They are frontline therapies for hypertension, depression, shock, asthma, angina & etc.
drugs target:
April 10, 2023 4
Tyrosine hydroxylase can be inhibited by methyl-p-tyrosine.
MAO: inhibitors of MAO (e.g., phenelzine, tranylcypromine)
The mobile pool; many indirect-acting sympathomimetics (e.g., amphetamine, ephedrine, tyramine) can displace NE from the mobile pool
Uptake: some indirect-acting sympathomimetics (cocaine, TCA).
Drug Targets
April 10, 2023 5
Prejunctional α-receptors: (e.g., clonidine, alpha methyldopa) cause inhibition of NE release.
Granular uptake of NE: blocker of granular uptake of NE (e.g., reserpine) .
NE release from granules: blockers (e.g., guanethidine).
Postjunctional receptors: postjunctional receptors can be activated or blocked.
Drug Targets
Classification
April 10, 2023 6
divided into subgroups on the basis of their
Spectrum of action: α, β, or dopamine
receptor affinity Mode of action: direct, indirect or
both
April 10, 2023 7
Adrenergic agonists Direct acting:I. α agonists: • Non selective, • α1-selective, • α2-selective II. β agonists: • Non selective, • β1-selective, • Β2-selective
April 10, 2023 8
Indirect acting ↑ CAO in the synapse:
1. Releaser: Amphetamine, tyramine
Potentiate by MAOI, COMT blocker. Why?
2. Reuptake inhibitor: Cocaine, TCA Mixed: Ephedrine, metaraminol
Adrenergic agonists
April 10, 2023 9
Removal of NE may:
Diffuse out and enter the general circulation. Be metabolized by COMT in the synaptic Be recaptured by an uptake systems into the
neuron
April 10, 2023 10
Adrenoceptors
Selective for NE & EP. dopamine can also activate some adrenoceptors at
very high ‘supraphysiologic’ concentrations.
Divided into two main classes: α & β adrenoceptors All are members of GPCR superfamily.
April 10, 2023 11
α-receptors: EP≥NE>>Isoproterenol
β-receptors: Isop>EP>NE
April 10, 2023 12
April 10, 2023 13
based on their affinities for a agonists and blocking drugs, α-receptors are subdivided into two subgroups α1 & α2,
e.g., α1 receptors have a higher affinity for phenylephrine than do α2 receptors.
Conversely, clonidine selectively binds to α2 receptors and has less effect on α1 receptors.
α-adrenoceptors (α1 & α2)
April 10, 2023 14
α-receptors: α1 Are present on the postsynaptic membrane
α2 Located primarily on presynaptic nerve endings.
The stimulation of α2 receptors causes feedback inhibition of the ongoing release of NE;
α2 Located on other cells such as the β-cell of the pancreas control insulin output.
April 10, 2023 15
April 10, 2023 16
β-receptors:
Subdivided to β1, β2 and β3-receptors β1-receptors have ~equal affinities for both EP &
NE., β2-receptors have higher affinity for EP than for
NE. thus tissue with a predominance of β2-receptors
(vasculature of skeletal muscle) are particularly responsive to hormonal effects of circulating EP released by adrenal medulla.
April 10, 2023 17
β-receptors
Mechanism of action: binding of neurotransmitter at the β1 or β2-receptor→
result in activation of AC→↑cAMP concentrations within the cell.
April 10, 2023 18
Mechanisms of action of adrenergic receptors :
April 10, 2023 19
April 10, 2023 20
Desensitization of receptors:
Prolonged exposure to the CAO reduces the responsiveness of the receptors due to:
1. Sequestration of the receptors
2. Downregulation (destruction, or decreased synthesis)
3. An inability to couple to G-protein
April 10, 2023 21
A. Catecholamine properties:
High potency in activating α & β receptors Rapid inactivation by:
1. COMT postsynaptically, gut wall,
2. MAO intraneuronally, liver or gut
Thus,
CAO have only a brief duration of action when given parenterally, and are ineffective when administered orally because of inactivation.
Poor penetration into the CNS (polar)
April 10, 2023 22
B. Non Catecholamine properties :
phenylephrine, ephedrine, amphetamine Have longer t1/2 because they are not inactivated by
COMT, and they are poor substrate for MAO Increased lipid solubility permits the greater access to
the CNS
April 10, 2023 23
Major effects mediated by adrenoceptors
April 10, 2023 24
SITE OF ACTION
April 10, 2023 25
SITE OF ACTION